S87314 |
Morinidazole |
源葉(MedMol) | 98% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.7 ml | 18.499 ml | 36.998 ml |
5 mM | 0.74 ml | 3.7 ml | 7.4 ml |
10 mM | 0.37 ml | 1.85 ml | 3.7 ml |
50 mM | 0.074 ml | 0.37 ml | 0.74 ml |
- 提示:詳情請(qǐng)下載說(shuō)明書。
- 產(chǎn)品描述: Morinidazole shows antibacterial activity and can be used in studies about bacterial infections research such as appendicitis and pelvic inflammatory disease caused by anaerobic bacteria.
- 靶點(diǎn): Antibacterial
- 體外研究:
Morinidazole shows antibacterial activity against Trichomonas vaginalis and Entamoeba histolytica with MICs of 2 and 3 μg/mL
- 體內(nèi)研究:
Morinidazole (20 and 25 mg/kg; p.o.) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo[2]. In the renal failure model in SD rats, Morinidazole (50 mg/kg; i.v.) shows a higher concentration in the liver, plasma, and kidney than lung, spleen, and heart
- 參考文獻(xiàn):
1. Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(7):4153-61. 2. Lu Aifeng, et al. Application of α-(morpholine-1-yl)methyl-2-methyl-nitroimidazole-1-ethanol as anti-trichomonal agent and amebacide: China, CN1981764[P]. 2007-06-20. 3. Kong F, et al. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins. Drug Metab Dispos. 2017 Jun;45(6):593-603.
- 溶解性: Soluble in DMSO
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 3.7 ml 18.499 ml 36.998 ml 5 mM 0.74 ml 3.7 ml 7.4 ml 10 mM 0.37 ml 1.85 ml 3.7 ml 50 mM 0.074 ml 0.37 ml 0.74 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)